Your address will show here +12 34 56 78
Accelerated
Timeline
A look at the project’s targets
and aggressive development timeline.
Drug Development
Upon incorporation of the company in March, our scientists were already able to complete the molecular design. We immediately engaged and executed contracts for formulation and manufacturing partners to begin developing the initial batch.

As of mid-May 2020, sixty-six percent (66%) of components of the initial batch was fully fabricated. The first batch of RELIVIR® developed for preclinical testing is targeted to be delivered by the end of June 2020. This is being performed through parallel groups in the United States.
Media
A significant media announcement will be made over the results of preclinical data. Because of the nature of how the product works, a proper communication of this model and the positive test results from our animal studies should make it clear to the public that the technology and results would translate easily into human subjects. 
Compassionate Use
Upon completion of preclinical work, we move directly to human clinical trials. Our clinical trial team is already preparing the protocols. We are arranging for parallel human clinical trials in multiple countries. This includes applications in several European countries in addition to the United States and others.

With the Asian origin of this virus together with the support from our original network in Southeast Asia, we will likely initiate the first human trials in the Philippines, due to an accelerated pathway that has been provided. 

The Philippine government has developed a dedicated task force called the Inter-Agency Task Force – Emerging infectious disease (IATF-EID) for COVID-19 that spans multiple government agencies. Prior to NUCISION, the CEO and Founders were nobly responsible for the first molecular FDA approval in the Philippines. 

We will implement the clinical studies in partnership with the government, clinical institutions, academic groups, and other research organizations. 

The Office of the Philippine President (OP) and the IATF-EID committee have already been working with NUCISION since March to support this initiative.
  • Text Hover
  • Text Hover
Preclinicals
We will engage in preclinical studies, which will include animal studies and other related safety work for the product. Our current site is a virology lab located in Rotterdam, Netherlands. The process is estimated to take thirty (30) days, which is shorter than typical timelines. This is possible, because:

(1) The mode of action does not require an immunogenic response to accomplish its target of virus destruction.

(2) The components of the core formulation are anticipated to be generally safe, since everything centers around a native human enzyme.

Human Clinical Trials
A significant media announcement will be made on the result of the preclinical data. Human clinical trials will be performed in countries that offer a favorable climate for such trials to be conducted. As our model involves a native human enzyme and a complex with high biocompatibility, we expect a high safety profile with this drug.
Go Global!
NuCISION will then enter into multi-country distribution licensing negotiations for commercialization. We anticipate support from international organizations to facilitate this process.

In parallel to our own development of a direct distribution network, a global licensing deal with an existing Big Pharma distributor is being considered. Members of NuCISION are industry veterans and are well-connected to the top leadership of Big Pharma.
  • Text Hover
Drug Development
Upon incorporation of the company in March, our scientists were already able to complete the molecular design. We immediately engaged and executed contracts for formulation and manufacturing partners to begin developing the initial batch.

As of mid-May 2020, sixty-six percent (66%) of components of the initial batch was fully fabricated. The first batch of RELIVIR® developed for preclinical testing is targeted to be delivered by the end of June 2020. This is being performed through parallel groups in the United States.
  • Text Hover
  • Text Hover
Preclinicals
We will engage in preclinical studies, which will include animal studies and other related safety work for the product. Our current site is a virology lab located in Rotterdam, Netherlands. The process is estimated to take thirty (30) days, which is shorter than typical timelines. This is possible, because:

(1) The mode of action does not require an immunogenic response to accomplish its target of virus destruction.

(2) The components of the core formulation are anticipated to be generally safe, since everything centers around a native human enzyme.

  • Text Hover
  • Text Hover
Media
A significant media announcement will be made over the results of preclinical data. Because of the nature of how the product works, a proper communication of this model and the positive test results from our animal studies should make it clear to the public that the technology and results would translate easily into human subjects. 
  • Text Hover
  • Text Hover
Human Clinical Trials
A significant media announcement will be made on the result of the preclinical data. Human clinical trials will be performed in countries that offer a favorable climate for such trials to be conducted. As our model involves a native human enzyme and a complex with high biocompatibility, we expect a high safety profile with this drug.
  • Text Hover
  • Text Hover
Compassionate Use
Upon completion of preclinical work, we move directly to human clinical trials. Our clinical trial team is already preparing the protocols. We are arranging for parallel human clinical trials in multiple countries. This includes applications in several European countries in addition to the United States and others.

With the Asian origin of this virus together with the support from our original network in Southeast Asia, we will likely initiate the first human trials in the Philippines, due to an accelerated pathway that has been provided. 

The Philippine government has developed a dedicated task force called the Inter-Agency Task Force – Emerging infectious disease (IATF-EID) for COVID-19 that spans multiple government agencies. Prior to NUCISION, the CEO and Founders were nobly responsible for the first molecular FDA approval in the Philippines. 

We will implement the clinical studies in partnership with the government, clinical institutions, academic groups, and other research organizations.

The Office of the Philippine President (OP) and the IATF-EID committee have already been working with NUCISION since March to support this initiative.
  • Text Hover
  • Text Hover
Go Global!
NUCISION will then enter into multi-country distribution licensing negotiations for commercialization. We anticipate support from international organizations to facilitate this process.

In parallel to our own development of a direct distribution network, a global licensing deal with an existing Big Pharma distributor is being considered. Members of NUCISION are industry veterans and are well-connected to the top leadership of Big Pharma.
  • Text Hover
Is a revolutionary company offering a unique
Platform antiviral solution to SARS-CoV-2
and future viral pandemics.

Need to know more about our therapeutic?
Ask about
  • Text Hover
  • Text Hover
Birth of the Next Generation Antiviral

Alpharetta, Georgia info@NuCISION .com

Copyright 2020 | Legal